← Evidence map

ArticleInflammatory bowel diseases2024

Correction to: Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2024

this papercites it

Correction to: Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. | OpenQuestion